SCHEMBL4985168

SCHEMBL4985168

CNC(=O)CN(C)c1n[nH]c2ccc([N+](=O)[O-])cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.49
MAPT P10636 3/20 0.45
HPGD P15428 2/20 0.45
CNR2 P34972 3/20 0.42
CSNK2A1 P68400 1/20 0.42
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
LMNA P02545 1/20 0.40
NQO2 P16083 1/20 0.39
CNR1 P21554 1/20 0.39
CYP1A2 P05177 1/20 0.38
GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4784577 0.87 MAPT (0.51) CDK2MAPTHPGDCNR2CSNK2A1
SCHEMBL4994251 0.86 MAPT (0.47) CDK2MAPTHPGDCNR2CSNK2A1
SCHEMBL4781566 0.82 MAPT (0.44) CDK2MAPTHPGDCNR2CSNK2A1
SCHEMBL4989629 0.81 GSK3B (0.42) KDM4ECYP1A2GSK3B
SCHEMBL4783739 0.80 MAPT (0.50) CDK2MAPTHPGDCNR2CSNK2A1
SCHEMBL4989156 0.80 MAPT (0.45) CDK2MAPTHPGDCNR2CSNK2A1
SCHEMBL16215476 0.79 MAPT (0.57) CDK2MAPTHPGDCNR2CSNK2A1
SCHEMBL16241349 0.76 JAK2 (0.50) CDK2CSNK2A1GSK3B
SCHEMBL2472386 0.74 CSNK2A1 (0.60) CDK2MAPTHPGDCNR2CSNK2A1
SCHEMBL15521004 0.72 MAPT (0.52) CDK2MAPTHPGDCNR2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-26 US disclosed
WO-2008061109-A2 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153810-A1 INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS MCHR1, MCHR2, MC1R CDK2 2227/4885MAPT 1651/4885HPGD 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.